Articles by R. Christian Moreton - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by R. Christian Moreton

R. Christian Moreton

vice-president, pharmaceutical sciences

R. Christian Moreton, PhD, is vice-president of pharmaceutical sciences at Finnbrit Consulting and a member of Pharmaceutical Technologys editorial advisory board.

Articles
Toward Expanding Understanding
March 2, 2011

A revised book on process analytical technology could be valuable to novices and experts.

Flexible Approaches to Accommodate Excipient Variability Using the Principles of QbD
May 1, 2010

The authors review new regulatory expectations and describe potential approaches to accommodate excipient variability. This article is part of PharmTech's supplement "Solid Dosage and Excipients 2010."

The Continuing Story of Nanoparticles
November 2, 2007

A book illustrates the potential for nanoparticulate drug delivery, and how much about them remains to be understood.

Manufacturing One Trend at a Time
October 2, 2007

Change is inevitable, as is contract manufacturing. But which companies will survive the drifts?

Functionality and Performance of Excipients
October 1, 2006

This article provides an overview of functionality, functionality-related characteristics, and excipients performance.

Excipient Functionality
May 2, 2004

The author suggests that an excipient's functionality can only be determined in the context of a specific formulation and manufacturing process.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
FindPharma Custom Search
Click here